Search company, investor...

Predict your next investment

Innopolis Partners company logo
Venture Capital
innollc.com

Investments

39

Portfolio Exits

1

Funds

2

About Innopolis Partners

Innopolis Partners is an independent venture capital firm in Korea that focuses on tech-oriented startups.

Headquarters Location

11F, SH Tower 331, Bongeunsa-ro, Gangnam-gu

Seoul, 06103,

South Korea

+82 (02)541-4838

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Innopolis Partners News

Health Diagnostics Company Mediwhale Raises $9 Million

Apr 19, 2023

Mediwhale – an AI-empowered health diagnostics company that uses retina scans to diagnose future cardiac and kidney disorder risk quickly and easily – announced it has closed a Series A funding round of $9 million with investors from the United States and South Korea. SBI Investment led the round and was one of four returning investors including BNK Venture Capital, Innopolis Partners, and IPS Ventures. Woori Venture Partners and HeartX Fund joined as first-time investors. And Mayo Clinic, Arizona State University, Medaxiom, and the HealthTech Arkansas Program also became shareholders in this round. Mediwhale is participating in 3 accelerator programs, including MedTech Accelerator Program by the Mayo Clinic and Arizona State University Alliance for Health Care, HeartX, and the Stanford University-affiliated StartX. Reti-Intelligence utilizes non-invasive retinal scans through a common fundus camera combined with extensively trained deep-learning algorithms to detect disease risks even before symptoms appear. And this initial assessment, conducted in primary care in less than one minute, can save patients time, and money, and the negative impacts of diseases that otherwise could go undetected. Mediwhale’s focus areas are cardiovascular (Reti-CVD), kidneys (Reti-CKD), eyes (Reti-Eye), and aging (Reti-Age). And Reti-Eye shows a minimum of 96% accuracy and Reti-CVD predicts cardiovascular risk as accurately as a cardiac CT. With the Series A funding round, Mediwhale plans to accelerate the global commercialization of Reti-CVD. And the company aims to increase sales and position itself as a leader in the global AI healthcare market. On top of the product approvals in 8 territories including South Korea, the European Union, and the UK, Mediwhale is taking steps to establish a foundation for entering the U.S. market by obtaining FDA approval and implementing U.S. insurance coverage with a goal of final FDA approval by 2024. And Mediwhale also aims to secure additional clinical evidence in the U.S. to further solidify its accuracy and validity. Mediwhale’s journey started in 2016 when the co-founders met under unfortunate circumstances. Kevin T. Choi, a recent graduate student, was a patient of Dr. Tyler H. Rim, a vitreoretinal surgeon, being treated for advanced glaucoma. And the diagnosis came too late, and Choi lost nearly 40% of his vision. Following the treatment, both Choi and Rim shared a strong interest in using machine learning to aid prevention, and together they founded Mediwhale to bring this to fruition. And they were determined to advance non-invasive technology and bridge the healthcare gap between medical professionals and communities by enabling individuals to learn about their health risks early. Choi and Rim added award-winning computer scientist Young G. Lee to develop the algorithm and AI solutions that Mediwhale is trailblazing today. Choi serves as CEO; Rim is Chief Medical Officer and Lee is Chief Technology Officer. KEY QUOTES: “The digital health care market is growing rapidly thanks to the development and application of AI technology. As validated in the top peer-reviewed medical journals, Mediwhale has shown great potential to set a new biomarker in diagnosis and prevention of cardiovascular disease. We expect Mediwhale to become a global healthcare gamechanger in the near future.” – Sungyeop Jang, the director of Woori Venture Partners “Mediwhale is a startup that helps both patients and healthcare professionals prevent and manage cardiovascular diseases with a simple eye test. We believe the success in securing investment in a challenging environment is due to investors resonating with our vision. We are striving to make this important technology available in clinical settings worldwide.” – Mediwhale CEO Kevin Choi

Innopolis Partners Investments

39 Investments

Innopolis Partners has made 39 investments. Their latest investment was in Egnis as part of their Series B - II on September 9, 2023.

CBI Logo

Innopolis Partners Investments Activity

investments chart

Innopolis Partners Portfolio Exits

1 Portfolio Exit

Innopolis Partners has 1 portfolio exit. Their latest portfolio exit was OPENEDGES on September 26, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/26/2022

IPO

$99M

Public

1

Date

9/26/2022

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

1

Innopolis Partners Fund History

2 Fund Histories

Innopolis Partners has 2 funds, including Innopolis No.1 Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/1/2007

Innopolis No.1 Fund

Expansions & Growth

Closed

$87.44M

1

2011KIF-Inno IT Fund

Subscribe to see more

Subscribe to see more

10

Closing Date

9/1/2007

Fund

Innopolis No.1 Fund

2011KIF-Inno IT Fund

Fund Type

Expansions & Growth

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$87.44M

Sources

1

10

Innopolis Partners Team

1 Team Member

Innopolis Partners has 1 team member, including current Chief Executive Officer, DongWon Park.

Name

Work History

Title

Status

DongWon Park

Chief Executive Officer

Current

Name

DongWon Park

Work History

Title

Chief Executive Officer

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.